Improved Exercise Myocardial Perfusion During Lidoflazine Therapy
- Treat stable angina with just one drug at a time. // Modern Medicine;Apr96, Vol. 64 Issue 4, p12
Reports on the treatment of stable angina pectoris with just one drug at a time instead of combination therapies, according to the study done by Stefano Savonitto and colleagues from Niguarda Ca'Granda Hospital in Milan, Italy. Publication of the study in the February 1996 issue of the `Journal...
- Pharmacological treatment of chronic stable angina pectoris. Tarkin, Jason M.; Kaski, Juan Carlos // Clinical Medicine;Feb2013, Vol. 13 Issue 1, p63
Chronic stable angina is the most common manifestation of ischaemic heart disease in the developed world and is associated with impaired quality of life and increased mortality. The pathogenesis of stable angina is complex and often, albeit not always, involves flow-limiting epicardial coronary...
- MINERVA. // BMJ: British Medical Journal;6/15/2013, Vol. 346 Issue 7912, p40
The article presents comments from readers on various topics including the story of a genie and a type 2 diabetes patient, review on the efficacy of flavonoid containing compound on venous leg ulcer healing in adults, and the establishment of an adult-like intestinal microbiota among U.S. children.
- Antianginal combination reduces cardiac events, but causes headaches. // Modern Medicine;Aug97, Vol. 65 Issue 8, p53
Presents an abstract of `Effect of Transdermal Nitroglycerin or N-acetylcysteine, or Both, in the Long-Term Treatment of Unstable Angina Pectoris,' by D. Ardissino, P.A. Merlini, et al from the `Journal of the American College of Cardiology' dated April 1997.
- Selection and dosing of nitrates to avoid tolerance during sustained antianginal therapy. Shaw, Sonia V.; Hunter, Walter J.; Shirer, Alyson E. // Formulary;Jul99, Vol. 34 Issue 7, p590
Discusses the selection and dosing of nitrates to avoid tolerance during sustained antianginal therapy. Pharmacology; Pharmacokinetics; Nitrate tolerance; Dosage, formulations and pricing; Oral agents; Action; Safety; Regimen selection. INSET: Nitrate therapy: Guidance for formulary decision...
- Investigational drug said to cut need for heparin. McCann, Brian // Drug Topics;4/21/97, Vol. 141 Issue 8, p36
Discusses the results of two clinical trials of the platelet inhibitor Aggrastat (tirofiban) developed by Merck & Co. for angina patients. Potential to cut the risk of death and cardiac complications; Reduction of the need for heparin; Cost of widespread tirofiban use; Merck's plan to file a...
- Management of angina in the older adult. Tierney, Paul; McKenna, Niall // Nursing & Residential Care;Feb2014, Vol. 16 Issue 2, p78
No abstract available.
- Management of Microvascular Angina Pectoris. Lanza, Gaetano; Parrinello, Rossella; Figliozzi, Stefano // American Journal of Cardiovascular Drugs;Feb2014, Vol. 14 Issue 1, p31
Microvascular angina (MVA) is defined as angina pectoris caused by abnormalities of small coronary arteries. In its most typical presentation, MVA is characterized by angina attacks mainly caused by effort, evidence of myocardial ischemia on non-invasive stress tests, but normal coronary...
- Medical management of chronic stable angina. Yong Wee; Burns, Kylie; Bett, Nicholas // Australian Prescriber;Aug2015, Vol. 38 Issue 4, p131
Stable angina pectoris is characterised by typical exertional chest pain that is relieved by rest or nitrates. Risk stratification of patients is important to define prognosis, to guide medical management and to select patients suitable for revascularisation. Medical treatment aims to relieve...